Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
Earnings Data
Report Date
Nov 11, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.64Last Year’s EPS
-1.13Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant advancements in clinical trials, financial stability, and preparation for regulatory approval. However, increased net loss, rising G&A expenses, and potential market competition are noted challenges.Company Guidance
Clinical Trials Success and Publication
Mineralys announced pivotal data for their ASI, lorundrostat, from Launch-HTN and Advance-HTN trials, which were presented at leading conferences and published in prestigious journals.
Physician Survey Results
A survey of 300 cardiologists and primary care physicians indicated that 95% would likely prescribe lorundrostat broadly for patients with uncontrolled or resistant hypertension if approved.
Financial Position
Mineralys ended the quarter with $324.9 million in cash, cash equivalents, and investments, up from $198.2 million as of December 31, 2024, indicating financial stability to support operations into 2027.
Expansion of Medical Communications
Mineralys has expanded its medical communications team to support pre-launch readiness, indicating proactive steps towards commercialization.
Upcoming Regulatory Milestone
Mineralys has a pre-NDA meeting with the FDA scheduled for the fourth quarter of 2025, showing progress towards regulatory approval.
MLYS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MLYS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 12, 2025 | $13.51 | $13.56 | +0.37% |
May 12, 2025 | $15.01 | $15.19 | +1.20% |
Feb 12, 2025 | $9.66 | $10.63 | +10.04% |
Nov 11, 2024 | $14.92 | $13.38 | -10.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mineralys Therapeutics, Inc. (MLYS) report earnings?
Mineralys Therapeutics, Inc. (MLYS) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).
What is Mineralys Therapeutics, Inc. (MLYS) earnings time?
Mineralys Therapeutics, Inc. (MLYS) earnings time is at Nov 11, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MLYS EPS forecast?
MLYS EPS forecast for the fiscal quarter 2025 (Q3) is -0.64.